Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. reported significant developments in its product pipeline and financial results for the fourth quarter and full year, leading to a rise in share prices during premarket trading [1]. Financial Performance - The company reported a fourth-quarter loss of $3.98 per share, which was worse than the consensus loss estimate of $3.16. However, sales reached $5.39 million, exceeding the consensus estimate of $2.88 million [2]. - As of December 31, 2025, Tonix Pharmaceuticals had approximately $207.6 million in cash and cash equivalents, which is expected to support operations into the first quarter of 2027 [4]. Product Pipeline and Market Engagement - Since the launch of Tonmya (cyclobenzaprine HCl sublingual tablets) in November 2025, over 1,500 healthcare providers have prescribed the drug, with approximately 2,500 patients initiating treatment and cumulative prescriptions totaling around 4,200 [2][3]. - The U.S. FDA approved Tonmya for fibromyalgia in adults in August 2025, marking it as the first new prescription medicine approved for this indication in over 15 years. The company is focusing on expanding payer engagement and establishing contracts with commercial payers while progressing discussions with Medicare and Medicaid [3]. Technical Analysis - Tonix Pharmaceuticals is currently trading 5.2% below its 20-day simple moving average (SMA) and 18.7% below its 100-day SMA, indicating a bearish trend in the short to medium term. Over the past 12 months, shares have decreased by 1.69% [5]. - The Relative Strength Index (RSI) is at 36.03, indicating neutral territory, while the MACD is at -0.6454, suggesting a potential for upward momentum as it is above the signal line [6]. Market Position - The Benzinga Edge scorecard indicates that Tonix Pharmaceuticals has a weak momentum score of 10.4, suggesting that the stock is underperforming relative to the broader market [7]. - During premarket trading, Tonix Pharmaceuticals shares were up 1.12% at $13.56 [8]. Key resistance is identified at $14.50, while key support is at $12.80 [9].